SNN
Smith & Nephew plc
NYSE · Healthcare · Medical - Devices · GB
$28.87
+0.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.2B | 6.2B | 5.8B | 5.5B | 5.2B |
| Cost of Revenue | 3.7B | 2.0B | 1.7B | 1.7B | 1.5B |
| Gross Profit | 8.5B | 4.2B | 4.1B | 3.9B | 3.7B |
| Operating Expenses | |||||
| R&D Expense | 702.0M | 346.0M | 343.0M | 339.0M | 345.0M |
| SG&A Expense | 6.0B | 3.0B | 2.9B | 2.8B | 2.7B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 206.0M | 31.0M | 175.0M | 297.0M | 198.0M |
| Total Operating Expenses | 6.9B | 3.4B | 3.4B | 3.5B | 3.3B |
| Cost and Expenses | 10.7B | 5.4B | 5.2B | 5.1B | 4.8B |
| Operating Income (EBIT) | 1.6B | 794.0M | 657.0M | 425.0M | 450.0M |
| Non-Operating | |||||
| Interest Income | 43.1M | 28.1M | 24.0M | 34.1M | 14.0M |
| Interest Expense | 302.5M | 141.3M | 150.1M | 132.5M | 80.0M |
| Net Interest Income | (259.4M) | (113.3M) | (126.1M) | (98.4M) | (66.0M) |
| Other Non-Op Income/Expense | (167.0M) | (15.0M) | (159.0M) | (135.0M) | (215.0M) |
| Non-Operating Income (excl Interest) | (312.0M) | (83.0M) | (229.0M) | (316.0M) | (208.0M) |
| EBT (Pre-Tax Income) | 1.4B | 779.0M | 498.0M | 290.0M | 235.0M |
| Income Tax Expense | 278.0M | 154.0M | 86.0M | 27.0M | 12.0M |
| Bottom Line | |||||
| Net Income | 1.1B | 625.0M | 412.0M | 263.0M | 223.0M |
| Earnings from Cont. Ops | 1.1B | 625.0M | 412.0M | 263.0M | 223.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.1B | 625.0M | 412.0M | 263.0M | 223.0M |
| Per Share | |||||
| Basic EPS | $2.64 | $1.46 | $0.94 | $1.20 | $0.50 |
| Diluted EPS | $2.60 | $1.44 | $0.94 | $1.20 | $0.50 |
| Revenue Per Share | $28.45 | $14.22 | $13.26 | $25.48 | $11.92 |
| Shares | |||||
| Basic Shares Outstanding | 430.4M | 433.4M | 438.3M | 217.8M | 437.6M |
| Diluted Shares Outstanding | 430.4M | 436.5M | 438.3M | 218.4M | 437.6M |
| Profitability Metrics | |||||
| EBITDA | 2.8B | 1.3B | 1.3B | 1.2B | 1.1B |
| D&A | 935.0M | 459.0M | 449.0M | 473.0M | 492.0M |
| EBIT | 1.9B | 877.0M | 886.0M | 741.0M | 658.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026